NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists. (SAN ANTONIO) January 9, 2023 –– Dr. Alexander I. Spira of Virginia Cancer Specialists (VCS) and Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, are pleased to announce the grand opening of their joint venture, NEXT Virginia, on January 12 to expand access to …
ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM
Paris (France), January 25th, 2023 – 6pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative tumor specific drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today provides an update on the clinical development program of its first-in-class drug candidate AsiDNATM. Onxeo activated its first …
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors
SAN FRANCISCO, November 1, 2022 – Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced that the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an …
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors
Multi-center Phase 1/2 study to evaluate safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing – Cannabinoid CB2 receptors are found in many difficult-to-treat cancers, including lung, renal, and ovarian cancers – Inhibiting CB2 receptors has the potential to …
The Theresa Mays Endowed Merit Award Established for Promising Investigators Holding a PharmD Degree
(SAN ANTONIO) November 1, 2022 –– The Theresa Mays Endowed Merit Award has been established to promote the education and advancement of oncology research for pharmacists. The award has been established with the support of friends and colleagues to recognize the life and legacy of Theresa Mays, BS, PharmD, BCOP, FASHP, and Vice President of Investigational Drug Services at NEXT …
Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board
Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony Tolcher, M.D., to advise Bright Peak in its mission to develop next-generation multifunctional precision immunotherapies for cancer – October 18, 2022 — SAN DIEGO, California & BASEL, Switzerland — Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein …
NEXT Oncology Selects proXimityTM to Automate Data Transfer for Clinical Trials
System will accelerate performance evaluation of new drugs in early phase research for cancer patients. (SAN ANTONIO) October 17, 2022 –– NEXT Oncology has selected proXimityTM as the exclusive tool to automate the transfer of clinical trial data from their electronic medical record (EMR) to the electronic data capture (EDC) systems used by sponsor organizations doing clinical trials with NEXT …
Research shows that cancer death rates are dropping across the country
AN ANTONIO – Cancer death rates are dropping across the country, according to the American Association for Cancer Research. There are more than 18 million cancer survivors in the U.S., proving that more people are living longer, fuller lives after being diagnosed. Doctors say new treatments, diagnostic tools, and prevention strategies have helped with the decline in deaths. Dr. Anthony …
NEXT Oncology’s Dr. Anthony Tolcher Presents Data on Well-Tolerated Monotherapy
for Advanced and Metastatic Tumors at ESMO Congress 2022
DCC-3116 is a first-in-class inhibitor of autophagy. (SAN ANTONIO) September 16, 2022 –– Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, returned from the European Society for Medical Oncology (ESMO) in Paris, France, where he presented the findings of a phase I, first-in-human study that evaluates DCC-3116 alone and in combination with MAPK pathway inhibition in patients with MAPK …
Alexander I. Spira, MD, PhD, FACP, Provides an Overview of the Use of Adagrasib in Advanced KRAS G12C–Mutant NSCLC at ASCO 2022
In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Annual Meeting, Alexander I. Spira, MD, PhD, FACP, a medical oncologist and co-director of the Virginia Cancer Specialists Research Institution, and director of the Thoracic and Phase I Program and clinical assistant professor at Johns Hopkin, discusses the safety profile of adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C–mutated non–small cell …